Microba Life Sciences (MAP) H1 2025 earnings summary

Executive summary

• Revenue for H1 FY25 reached $8.08 million, up 147% year-over-year, driven by strong MetaXplore test sales in Australia and steady UK performance during a transition phase.

• Net loss after tax decreased by 50% to $5.74 million compared to the same period last year, reflecting increased scale and reduced R&D expenditure.

• Gross profit rose to $3.83 million from $1.38 million year-over-year, with total operating expenses reduced from $16.75 million to $13.84 million.

• Cash and equivalents stood at $17.3 million as of 31 December 2024.

Financial highlights

• H1 revenue: $8.08 million, up 147% year-over-year.

• H1 cash receipts: $8.98 million, up 144% year-over-year.

• Net loss after tax: $5.74 million, down 50% year-over-year.

• Gross profit: $3.83 million, up from $1.38 million year-over-year.

• No dividends declared or paid during the period.

Outlook and guidance

• Confident in continued growth for MetaXplore and MetaPanel in Australia and UK, with full UK market access expected by end of FY25.

• Plans to advance MAP 315 to Phase 2 clinical trial for IBD and pursue non-dilutive strategic opportunities.

• Focused on expanding UK growth and US entry with public reimbursement for MetaPanel.